These data indicate that co-treatment with CB might antagonize the DEX-induced inhibitory effect on IGF1 expression, and this effect of CB might also be associated with its protective effect against DEX-induced muscle atrophy, in addition to activation of the Akt/mTOR pathway. The gene discussed is IGF1; the disease is muscle atrophy.